First Tracks Biotherapeutics, Inc. TRAX
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) is an immunology/inflammation drug developer. Its lead program, Rosnilimab, is in Phase 2 for rheumatoid arthritis. Its next catalyst on record is ANB033: Cohort 2 enrollment completing imminently; topline Q1 2027. (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ANB033 — Cohort 2 enrollment completing imminently; topline Q1 2027. (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Rosnilimab | rheumatoid arthritis (Phase 2b completed; EOP2 meeting held Q1 2026) | antibody | Phase 2 |
| Rosnilimab | ulcerative colitis (Phase 2, not positive) | antibody | Phase 2 |
| ANB033 | celiac disease (Phase 1b, ~70 pts, Fast Track) | antibody | Phase 1 |
| ANB033 | eosinophilic esophagitis (Phase 1b, 50 pts) | antibody | Phase 1 |
| ANB101 | BDCA2 modulator, autoimmune (healthy-volunteer Phase 1 completed Aug 2026) | antibody | Phase 1 |
Recent results and decisions
- Oct 19, 2026n/a First Tracks Biotherapeutics closed private placement of 6,106,870 shares of common stock on October 19, 2026.
On October 19, 2026 (the 'Closing Date'), First Tracks Biotherapeutics, Inc. (the 'Company') closed its previously announced private placement (the 'Private Placement') of an aggregate 6,106,870 shares (the 'Shares') of the Company's common stock, par value $0.001 per share.
Filing - Oct 12, 2026met Cohort 1 met key endpoints: Vh:Cd change -0.17 vs -0.66 placebo (+0.49, p=0.009); IEL density -20.03 vs placebo (p<0.001); symptoms prevented; no SAEs.
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms
Filing - Aug 12, 2026n/a FDA granted Fast Track designation to ANB033 for celiac disease.
U.S. FDA granted Fast Track designation for ANB033 for the treatment of CeD
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.